Celldex Therapeutics Inc. (NASDAQ: CLDX) Price Target Lowered Amid Clinical Trial Setback

• Cantor Fitzgerald adjusted its price target for Celldex Therapeutics Inc. to $61.00, down from $67.00, yet still indicating significant upside potential for the biopharmaceutical stock.
• The company halted its Phase 2 clinical trial for barzolvolimab, a key drug in its development pipeline, due to the treatment failing to meet its primary efficacy endpoints.
• Despite the clinical trial setback, Celldex maintains a strong safety profile for the drug and has other promising Phase 3 trials underway, with results anticipated in late 2026, offering potential future growth.

Celldex Therapeutics Inc. (NASDAQ: CLDX) is a biopharmaceutical company that develops treatments for specific diseases. The company focuses on therapies that target cells in the human immune system. It currently has a market capitalization of approximately $2.37 billion, which is the total value of all its shares.

On July 22, 2026, an analyst from Cantor Fitzgerald lowers the price target for Celldex to $61.00 from $67.00. A price target is an analyst's projection of a stock's future price. With the stock trading at $35.66, this new target still represents a potential increase of about 71.06% from its price when the report was published.

This adjustment follows the company's announcement that it is stopping its Phase 2 clinical trial for barzolvolimab. The drug was being tested as a treatment for prurigo nodularis, a chronic skin condition. A Phase 2 trial is designed to test if a drug is effective and to further evaluate its safety.

The study was terminated because it failed to achieve its main goals. As highlighted by Benzinga, the treatment did not show a meaningful improvement for patients compared to a placebo group. A placebo is a substance with no medical effect, used as a control to see if a new drug actually works.

Despite this setback in drug development, the drug showed a good safety profile. Celldex also has other studies underway, with results from a Phase 3 trial for another condition expected in late 2026. This ongoing research may be why the analyst's price target, though reduced, remains significantly higher than the current stock price, offering potential investment insights.